KRW 2545.0
(0.99%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 1.45 Billion KRW | 16.05% |
2022 | 1.25 Billion KRW | -94.22% |
2021 | 21.7 Billion KRW | 68.13% |
2020 | 12.91 Billion KRW | 102.85% |
2019 | 4.8 Billion KRW | 6.55% |
2018 | 10.98 Billion KRW | 4.08% |
2017 | 8.84 Billion KRW | 2.33% |
2016 | 9.66 Billion KRW | 5.29% |
2015 | 5.81 Billion KRW | 7.95% |
2014 | 4.53 Billion KRW | 4.09% |
2013 | 4.79 Billion KRW | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | 313.55 Million KRW | 398.12% |
2024 Q1 | -105.17 Million KRW | 98.77% |
2023 FY | 1.45 Billion USD | 16.05% |
2023 Q1 | 3.77 Billion USD | 95.83% |
2023 Q3 | 2.98 Billion USD | -13.71% |
2023 Q2 | 3.45 Billion KRW | -8.59% |
2023 Q4 | -8.56 Billion USD | -387.38% |
2022 FY | 1.25 Billion USD | -94.22% |
2022 Q3 | 2.75 Billion USD | 0.0% |
2022 Q1 | 2 Billion USD | 12.39% |
2022 Q4 | 1.93 Billion USD | -29.97% |
2021 Q4 | 1.78 Billion USD | -30.48% |
2021 FY | 21.7 Billion USD | 68.13% |
2021 Q1 | 1.91 Billion USD | 14.28% |
2021 Q3 | 2.56 Billion USD | 0.0% |
2020 Q1 | 1.49 Billion USD | -0.69% |
2020 Q3 | 2.41 Billion USD | 0.0% |
2020 Q4 | 1.67 Billion USD | -30.56% |
2020 FY | 12.91 Billion USD | 102.85% |
2019 Q1 | 1.49 Billion USD | 12.6% |
2019 Q3 | 2.13 Billion USD | 0.0% |
2019 FY | 6.36 Billion USD | 6.55% |
2019 Q4 | 1.5 Billion USD | -29.54% |
2018 Q4 | 1.32 Billion USD | -30.55% |
2018 FY | 5.97 Billion USD | 4.08% |
2018 Q3 | 1.9 Billion USD | 0.0% |
2018 Q1 | 1.42 Billion USD | 11.43% |
2017 FY | 5.73 Billion USD | 2.33% |
2017 Q1 | 1.37 Billion USD | 14.34% |
2017 Q3 | 1.85 Billion USD | 0.0% |
2017 Q4 | 1.27 Billion USD | -31.12% |
2016 FY | 5.6 Billion USD | 5.29% |
2016 Q4 | 1.2 Billion USD | -32.83% |
2016 Q3 | 1.79 Billion USD | 0.0% |
2016 Q1 | 1.37 Billion USD | 15.11% |
2015 Q3 | 1.72 Billion USD | 0.0% |
2015 Q1 | 1.3 Billion USD | 10.72% |
2015 FY | 5.32 Billion USD | 7.95% |
2015 Q4 | 1.19 Billion USD | -31.08% |
2014 FY | 4.93 Billion USD | 4.09% |
2014 Q1 | 1.21 Billion USD | 12.09% |
2014 Q3 | 1.59 Billion USD | 0.0% |
2014 Q4 | 1.17 Billion USD | -26.24% |
2013 Q1 | 1.14 Billion USD | 18.79% |
2013 Q4 | 1.08 Billion USD | -32.33% |
2013 FY | 4.74 Billion USD | 0.0% |
2013 Q3 | 1.6 Billion USD | 0.0% |
2012 Q4 | 961.98 Million USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
HLB Co., Ltd. | -6.01 Billion KRW | 124.233% |
iNtRON Biotechnology, Inc. | 4.56 Billion KRW | 68.054% |
BINEX Co., Ltd. | 56.65 Billion KRW | 97.428% |
Bioneer Corporation | 199.25 Billion KRW | 99.269% |
Anterogen.Co.,Ltd. | 2.21 Billion KRW | 34.175% |
MEDIPOST Co., Ltd. | 40.18 Billion KRW | 96.374% |
Helixmith Co., Ltd | 2.12 Billion KRW | 31.333% |
Chabiotech Co.,Ltd. | 255.19 Billion KRW | 99.429% |
Medy-Tox Inc. | 128.16 Billion KRW | 98.863% |
Peptron, Inc. | 1.14 Billion KRW | -27.743% |
Amicogen, Inc. | 51.51 Billion KRW | 97.172% |
Genexine, Inc. | 387.48 Million KRW | -276.016% |
HLB Therapeutics Co.,Ltd. | 6.69 Billion KRW | 78.235% |
LegoChem Biosciences, Inc. | 17.79 Billion KRW | 91.813% |
ALTEOGEN Inc. | 31.19 Billion KRW | 95.33% |
PharmaResearch Co., Ltd. | 182.25 Billion KRW | 99.201% |
SillaJen, Inc. | 1.45 Billion KRW | -0.018% |
JETEMA, Co., Ltd. | 26.58 Billion KRW | 94.519% |
OliX Pharmaceuticals,Inc | 14.42 Billion KRW | 89.898% |
Genomictree Inc. | -1.03 Billion KRW | 240.286% |
MedPacto, Inc. | -1.83 Billion KRW | 179.502% |
D&D Pharmatech | 18.67 Billion KRW | 92.199% |
EASY BIO,Inc. | 50.88 Billion KRW | 97.137% |
GI Innovation, Inc. | 1.98 Billion KRW | 26.762% |